Expanding on their 2007 co-marketing agreement on the service side, BioTrove and Agilent last month signed a non-exclusive value-added reseller agreement to enable BioTrove to provide enhanced options for users of its RapidFire mass spectrometry sample preparation system for mass spectrometry-based drug discovery.
High Throughput Genomics is young company, but one that has made an impact in the area of customized, high-throughput gene expression analysis. Its key technology is qNPA which allows for expression analysis without the need for RNA extraction, cDNA synthesis or RNA labeling or amplification. Last January, Tim “TJ” Johnson—ex of Ventana Medical Systems—took the helm of the company as CEO. TJ recently took time out of his schedule to chat with DDN Chief Editor Chris Anderson.
Clinical Data Inc. and Avalon Pharmaceuticals Inc. announced in late October that the companies entered into a definitive merger agreement for Clinical Data to acquire Avalon in a stock transaction valued at approximately $10 million.
Four in five Americans support the idea of a nationwide study to investigate the interactions of genes, environment and lifestyle, and three in five say they would be willing to take part in such a study, according to a survey released recently by the Genetics & Public Policy Center at Johns Hopkins University.
Ensemble Discovery Corp. recently extended a collaboration with Roche that will deploy Ensemble’s diagnostic assays in human clinical studies to analyze combinations of epidermal growth factor receptors (EGFR) present in various cancer tissues.
Translational research software firm GenoLogics Life Sciences Software Inc. announced Nov. 10 it signed a three-year, global agreement with Pfizer to provide informatics solutions to its research labs.
So far, it seems the pressure to produce increased profits is winning in the battle to transform the industry. But I wonder if, with all the external pressures on large pharma, we might soon be reaching the breaking point.
As Congress is considering possible legislation to create an abbreviated pathway for the FDA to approve generic biologic therapies, differences in the R&D expense and product cost, and the potential for both new therapies post-approval and second-generation innovations, have raised questions about how to achieve the proper balance between innovation and competition.